News

 

Nerviano Medical Sciences S.r.l. Expands US Presence

Nerviano Medical Sciences S.r.l. (NMS Srl), announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).

NMS-812 is a novel potent oral inhibitor of PERK (PKR-like endoplasmic reticulum kinase) that also inhibits GCN2 (General Control Nonderepressible 2). PERK and GCN2 are effectors of the Integrated Stress Response (ISR), a pro-survival pathway exploited by cancer cells to survive stress. PERK is a key effector of the unfolded protein response (UPR) and GCN2 is a sensor of amino acid deficiency. Both proteins modulate the eIF2α/ATF4 axis promoting tumor survival and drug resistance as well as, via direct and indirect mechanisms, the immune response.
(Click the title for the complete article)

European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS Srl.

Nerviano, 13 May 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to share the publication on the current issue of the European Journal of Cancer of the first-in-human (FIH) study conducted with the MPS1 inhibitor NMS-01940153E discovered in Nerviano (Schöffski et al.; European Journal of Cancer, Volume 169, 2022).
(Click the title for the complete article)

Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy

Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy

Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione Regionale per la Ricerca Biomedica), Mr. Luigi Cajazzo, Managing director of FRRB and Mr. Massimiliano Amato, Board member of NMS Group SpA today. The delegation was warmly welcomed by Dr. Hugues Dolgos, the newly appointed CEO of NMS Group and CEOs of the Group’s subsidiaries Dr. Guoxian (Gregory) Wu, Mr. Angelo Colombo, and Mr. Giuseppe Vivolo. (Click the title for the complete article)

NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries

Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.
Following the Shareholders’ Meeting, the Company’s newly formed Board of Directors approved a new governance to accelerate the progression of the portfolio, to strengthen the competitive positions of Accelera and NerPharMa, and to optimize and deliver concrete values for its patients, shareholders, employees and community. Dr. Hugues Dolgos, a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology, was appointed as Chief Executive Officer (“CEO”) of the Company, effective immediately. (Click the title to read the complete article)

Entrectinib, the kinase inhibitor drug invented and initially developed by Nerviano Medical Sciences won the Prix Galien Italia 2021 Award in the Chemically Synthesized Drugs category

Entrectinib, the kinase inhibitor drug invented and initially developed by Nerviano Medical Sciences won the Prix Galien Italia 2021 Award in the Chemically Synthesized Drugs category

Nerviano, 5 November 2021
Entrectinib, the kinase inhibitor drug that was invented and initially developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has won the Prix Galien Italia 2021 award as an antitumor therapy with agnostic indication in the category of Chemically Synthesized Drugs.
(Click the title for the complete article)

Nerviano Medical Sciences Receives FDA “Study May Proceed” Letter for First-In-Human Phase 1 Clinical Trial under Its Investigational New Drug Application for NMS-03602173, a Dual IDH1/2 Inhibitor, in Advanced Solid Tumors

Nerviano, 22 October 2021
Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate NMS-03602173, a second-generation oral inhibitor of IDH1 and IDH2, in advanced solid tumors.
(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO